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INTRODUCTION
Globally, infertility impacts 15% of couples trying 
to conceive. The incidence of male infertility has been 
increasing over the past several decades, ranging from 
20% to 70% worldwide [1,2]. The male partner is found 
to be solely responsible in 20%–30% of cases, and con-
tributes to couple infertility in approximately 50% of 
cases [3]. The etiologies and risk factors for male infer-
tility are diverse. In addition to genetic causes, com-
mon acquired causes include varicocele, reproductive 
tract infections/inflammation, endocrine abnormalities, 
cryptorchidism, medications, malignancy, radiation and 
chemical or chemotherapy exposure, environmental 
Foggia, Italy, 32Department of Physiology, Faculty of Medicine, Bioscience and Nursing, MAHSA University, Kuala Lumpur, Malaysia, 
33Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, USA, 34Citmer Reproductive Medicine, IVF LAB, Mexico City, Mexico, 
35IVF Unit, Al Boustane Clinic, Rabat, Morocco, 36Fertility Medical Group, Sapientiae Institute, São Paulo, Brazil, 37Department of Urology, 
University of Santo Tomas Hospital, Manila, Philippines, 38GAO Bojović, Belgrade, Serbia, 39Deparment of Andrology, Fundacio Puigvert, 
Barcelona, Spain, 40Department of Urology, University of Ankara, Ankara, Turkey, 41Avant Concierge Urology & University of Central 
Florida, Winter Garden, FL, USA, 42Honorary Staff of Cooper University Hospital, Camden, NJ, USA, 43Anfa Fertility Center, Casablanca, 
Morocco, 44St. Barbara Clinic, Bad Vigaun, Austria, 45Andrology Unit, Instituto De Ginecologia y Fertilidad (IFER), Buenos Aires, Argentina, 
46Instituto Ideia Fertil-Human Reproduction Centre-Faculdade de Medicina do ABC, Sao Paulo, Brazil, 47Department of Andrology, 
Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran, 48IVF Japan Group, 
HORAC Grand Front Osaka Clinic, Osaka, Japan, 49Department of Anatomy and Unit for Multidisciplinary Research in Biomedicine (UMIB), 
Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal, 50Department of Urology, Military Medical 
Academy, Belgrade, Serbia, 51Urology VUK Center, Belgrade, Serbia, 52Department of Andrology, Hammersmith Hospital, London, UK, 
53Department of Obstetrics & Gynaecology, University College Hospital, Ibadan, Nigeria, 54Tiziri IVF Center, Algeriers, Algeria, 55American 
College of Embryology, Houston, TX, USA, 56Department of Urology, University of Queensland, Brisbane, Australia, 57Odyssèe Clinic for 
Assisted Reproduction, Douala, Cameroun, 58ANDROS Day Surgery Clinic, Reproductive Medicine Unit, Palermo, Italy, 59Department of 
Obstetrics and Gynecology, University of Nicosia Medical School, Nicosia, Cyprus, 60Biasa Fertility Clinic, Lomè, Togo, 61Department of 
Obstetrics and Gynecology, Bahcesehir University, Istanbul, Turkey, 62Middle East Fertility Society, Canadian Foundation for Reproductive 
Medicine, Lebanon, 63Reproductive Medicine Unit, New Jahra Hospital, Ministry of Health, Al Jahra, Kuwait, 64Fertimed Ltd., Olomouc, 
Czech Republic, 65RMU Dr. Arab Medical Center, Jeddah, Saudi Arabia, 66ANDROFERT, Andrology & Human Reproduction Clinic, 
Campinas, Brazil, 67Division of Urology, Department of Surgery, University of Campinas (UNICAMP), Campinas, Brazil, 68Section of 
Andrology, Istanbul Faculty of Medicine, Istanbul, Turkey, 69Department of Obstetrics and Gynecology, Bukovinian State Medical University, 
Chernivtsi, Ukraine, 70International Centre for Reproductive Medicine, Saint-Petersburg, Russia, 71Department of Urology, Lilavati Hospital 
and Research Centre, Mumbai, India
Purpose: The use of antioxidants is common practice in the management of infertile patients. However, there are no estab-
lished guidelines by professional societies on antioxidant use for male infertility.
Materials and Methods: Using an online survey, this study aimed to evaluate the practice pattern of reproductive specialists 
to determine the clinical utility of oxidative stress (OS) testing and antioxidant prescriptions to treat male infertility.
Results: Responses from 1,327 participants representing 6 continents, showed the largest participant representation being 
from Asia (46.8%). The majority of participants were attending physicians (59.6%), with 61.3% having more than 10 years of
experience in the field of male infertility. Approximately two-thirds of clinicians (65.7%) participated in this survey did not 
order any diagnostic tests for OS. Sperm DNA fragmentation was the most common infertility test beyond a semen analysis 
that was prescribed to study oxidative stress-related dysfunctions (53.4%). OS was mainly tested in the presence of lifestyle 
risk factors (24.6%) or sperm abnormalities (16.3%). Interestingly, antioxidants were prescribed by 85.6% of clinicians, for a 
duration of 3 (43.7%) or 3–6 months (38.6%). A large variety of antioxidants and dietary supplements were prescribed, and 
scientific evidence were mostly considered to be modest to support their clinical use. Results were not influenced by the 
physician’s age, geographic origin, experience or training in male infertility.
Conclusions: This study is the largest online survey performed to date on this topic and demonstrates 1) a worldwide under-
standing of the importance of this therapeutic option, and 2) a widely prevalent use of antioxidants to treat male infertility. 
Finally, the necessity of evidence-based clinical practice guidelines from professional societies is highlighted.
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and lifestyle factors, and underlying medical comorbid-
ities [4]. Despite the wide spectrum of potential causes, 
a large proportion of male infertility cases remain as 
unexplained male infertility (UMI) and/or idiopathic 
male infertility (IMI) when controlling for known fe-
male factors. In this context, oxidative stress (OS) has 
been established as an important etiology and/or com-
mon mechanism in many known and unknown causes 
of male infertility [5,6].
OS occurs when there is an imbalance between re-
active oxygen species (ROS) and antioxidants (AOX), 
resulting in sperm DNA fragmentation (SDF) and 
semen abnormalities [7]. The negative impact of OS 
on male infertility is supported by abnormal levels of 
seminal oxidation-reduction potential (ORP) in up to 
80% of males with IMI, a condition termed as male OS 
infertility (MOSI) [6]. Elevated OS can negatively im-
pact fertility through various pathways. OS can induce 
the formation of mutagenic or genotoxic by-products in 
germ cells and spermatozoa that may result in a nega-
tive impact on spermatogenesis, semen parameters, 
semen quality, fertilization, pregnancy, and health 
consequences for future progeny [8,9]. Therefore, male 
fertility potential cannot be fully evaluated unless 
seminal OS is included in the clinical assessment.
As OS is such a prominent cause or mechanism 
of male infertility, the utilization of AOX to reduce 
seminal ROS is an important therapeutic option to 
improve semen parameters and fertility. Due to their 
widespread availability, safety profile, and low cost 
compared to assisted reproduction, AOX and supple-
ments are a simple starting point for many infertile 
couples seeking to improve their chances of conceiving 
[10]. However, although considered low cost, AOX for 
male infertility are part of a large economic market for 
dietary supplements, estimated at USD 123.28 billion 
in 2019, with a forecasted growth rate of 8.2% annually 
until 2027 [11].
Commonly used AOX for male infertility include vi-
tamins A, C, and E, L-carnitines, N-acetyl cysteine, and 
Co-enzyme Q10, along with important AOX co-factors 
zinc, selenium, and folic acid. These and numerous 
others are included in various registered AOX formu-
lations [12-14] and food enriched with natural AOX 
[15,16]. Multiple studies have shown the benefit of AOX 
supplementation [17-19], and a recent Cochrane review 
found that oral AOX therapy may improve semen 
parameters and the likelihood of pregnancy [20]. How-
ever, the outcomes of clinical trials on the use of AOX 
in male infertility are not consistent, ranging from 
clear benefit [21] to no clinical effect [22], to even hav-
ing significant detrimental effects [23,24]. These con-
flicting findings may be due to reductive stress from 
improper dosing of AOX or from poor study design [25]. 
Regardless, these studies have caused confusion among 
patients and clinicians alike.
While the prescription of AOX as a therapeutic op-
tion is gaining increasing attention, the lack of clinical 
practice guidelines endorsed by professional associa-
tions strictly limits the standardization of clinical 
protocols [26,27]. Even though the topic has been inves-
tigated in a large number of publications [27], there is 
still no consensus on regimen, dosing, or length of AOX 
treatment. The dose and nature of AOX prescribed is 
variable and determined by the local availability of 
AOX products and the experience of the individual 
practitioner. Similarly, the length of treatment report-
edly varies between less than 2 months and up to 6 
months [27]. However, the global practice of recom-
mending AOX for infertile men by registered practi-
tioners in reproductive medicine is unclear. Therefore, 
this study aimed to conduct a comprehensive survey of 
reproductive specialists to determine the pattern of us-
ing OS tests and AOX prescriptions in male infertility 
based on the clinical experience of professionals in the 
field of infertility from around the world.
MATERIALS AND METHODS
1. Ethical statement
This global online survey on male infertility, OS test-
ing and AOX use was approved by the Institutional 
Review Board (IRB) of Cleveland Clinic (IRB No. 20-
855).
2. Survey design and participants
This cross-sectional observational study used an 
internet survey as a data collection tool. The survey 
was designed to investigate the use of  OS testing, 
AOX utilization and practice patterns of reproduc-
tive specialists involved in the care of patients with 
male infertility. A panel was formed consisting of 58 
experts actively involved in the management of male 
infertility patients from 28 different countries, which 
included clinicians, researchers and scientists involved 
in the field of OS, AOX, and male infertility. The sur-
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vey questions were carefully drafted, reviewed, and ap-
proved by these experts. SelectSurvey (https://www.cl-
assapps.com/product_ssv5.aspx), a secured tool approved 
by the Cleveland Clinic’s Information Technology 
Department, was used to populate the survey questions 
online. The survey was kept open for 3 months (August 
10th, 2020 to November 9th, 2020) for the participants 
to provide their response. During this time period, the 
online survey link was shared with the members of 
various professional societies and committees (as listed 
in the Acknowledgement section). The targeted partici-
pants of the survey were medical professionals work-
ing in the field of reproductive medicine and those in-
volved in the treatment of infertile couples. Incomplete 
or duplicate responses were excluded from the analysis.
3. Questionnaire design
The online survey was written in English and com-
posed of 29 questions that were structured into four 
different sections (Supplement File). The first section (4 
questions) was related to the demographics of the par-
ticipants; the second section (6 questions) was regard-
ing the profession and clinical practice of the respon-
dents; the third section (4 questions) was on OS testing 
in clinical practice; and the final section (15 questions) 
was related to the use of AOX in clinical practice.
4. Statistical analysis of data
Survey responses were downloaded in a comma-sep-
arated values (CSV) file format from the SelectSurvey 
application into a secured storage device approved by 
the Cleveland Clinic. Descriptive statistics was con-
ducted using MedCalc Software (version 19.0.5; Med-
Calc Software, Ostend, Belgium). Data was reported as 
the number of participants and percentage of the total 
who answered each survey section or relevant ques-
tion. However, participant numbers might be slightly 
different for some optional questions. For other ques-
tions, participants could mark more than one option, 
hence the results were reported as the percentage cal-
culated based on the total number of participants who 
answered. Results were analysed using chi-square test 
to examine the international trends of OS testing and 
AOX use by participants.
Table 1. Classification of survey participants according to demo-






South America 262 (19.7)
Europe 208 (15.7)
Africa 150 (11.3)
North America 57 (4.3)
Australia 29 (2.2)
Total 1,327 (100)








Medical education company 164 (12.8)
Pharmaceutical or dietary supplement  
company 
22 (1.7)
Market research company/advertising 
agency 
10 (0.8)
I am affiliated with MORE than one of the 
bodies mentioned in the table 
17 (1.3)
Other 68 (5.3)
I am NOT affiliated with any of the bodies 
mentioned in the table 
1,000 (78.1)
Total 1,281 (100)
D Nature of the employment
Attending physicians 780 (59.6)
Advanced practice provider (PA/NP) 210 (16.0)
Resident 83 (6.3)
Fellow 75 (5.7)






Laboratory director 7 (0.5)
Researcher 6 (0.5)
Fertility specialist 5 (0.4)
PhD student 5 (0.4)
Student 4 (0.3)
Biologist 3 (0.2)






After excluding duplicate or incomplete responses 
(those who did not continue with questions listed in 
section 2, n=150) from the analysis, a total of 1,327 par-
ticipants from 88 countries completed the online sur-
vey (Table 1). Not all the questions in each section were 
completed by each participant, as some were optional. 
The number of responses for each subsection is pro-
vided in Table 1. Geographical distribution of the par-
ticipants included Asia (46.8%), South America (19.7%), 
Europe (15.7%), Africa (11.3%), North America (4.3%) 
and Australia (2.2%). The majority of participants were 
aged 35–64 years old (75.0%), whereas the remaining 
were aged 25–34 years old (15.1%) or more than 65 
years old (9.9%).
A total of 1,281 (96.5%) participants responded to the 
self-reported nature of employment. Here, participants 
were identified primarily as attending physicians 
(59.6%) and advanced practice providers such as physi-
cian assistants and nurse practitioners (16.0%), along-
side resident (6.3%) or fellows (5.7%) and academic staff 
(3.5%). A total of 1,323 (99.7%) participants responded to 
the primary work setting, which was most prominently 
reported as private practice (35.7%) or academic hos-
pitals/clinics (26.9%). Out of 1,325 (99.8%) participants 
who responded to the question about their profession, 
nearly half (49.9%) reported themselves to be involved 
in more than one of the registered professions listed, 
while the most frequent self-reported single registered 
profession was in the field of urology (20.2%), andrology 
(8.8%) and gynecology (6.7%). The full cohort (n=1,327) 
responded to the questions about years of experience 
and specific training in male infertility. Here, most of 
these participants reported clinical practice experience 
of more than 10 years (61.3%), with special training in 
the field of male infertility either as part of their resi-
dency (47.5%) or fellowship (29.2%) training.
2. Oxidative stress testing
A total of 1,305 (98.3%) participants responded to the 
use of OS testing as part of male fertility evaluation, 
where 34.3% reported the use of OS testing in their 





E Primary practice setting
Private practice or clinic 472 (35.6)
Academic hospital or clinic 356 (26.9)
Public hospital or clinic 93 (7.0)
Non-academic private hospital or clinic 59 (4.5)
Other 14 (1.1)
Non-teaching community hospital 6 (0.5)












General practitioner 14 (1.1)
Obstetrics 12 (0.9)
Researcher 11 (0.8)




G Years of practicing
Less than 2 years 98 (7.4)
2–5 years 179 (13.4)
5–10 years 237 (17.9)
More than 10 years 813 (61.3)
Total 1,327 (100)
h Specialty training in the field of male infertility
Yes, as part of my specialty training  
(residency)
63 (47.5)





Values are presented as number (%). 
Survey participants were classified according to their responses regard-
ing their (A) geographical origin, (B) age, (C) affiliation, (D) nature of the 
employment, (E) primary practice settings, (F) registered profession, (G) 
years of practice, and (H) specialty training in male infertility.
SN: serial number, PA/NP: physician assistant/nurse practitioners.
Table 2. Participants (n=1,305) response to the use of oxidative 
stress-related biomarkers in the clinical evaluation of male infertility
Response
Oxidative stress testing as a part of  
the male fertility evaluation
Yes 448 (34.3)
No 857 (65.7)
Values are presented as number (%). 
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ducted to investigate the most commonly used assays 
to assess OS. Among the tests presented in Fig. 1, SDF 
(53.4%) was the most commonly utilized, followed by 
ORP (6.3%). Moreover, 31.3% reported using more than 
one assay to evaluate OS in infertile men (Fig. 1).
A total of 416/448 (92.9%) participants responded to 
the clinical conditions for OS testing. Survey results re-
vealed that 59% (n=249) of clinicians recommended OS 
testing for patients with abnormal semen parameters 
and 55.8% of clinicians ordered OS testing for patients 
with UMI (n=232) (Fig. 2A). Survey participants re-
ported that patients with risk factors such as smok-
ing, alcohol consumption or drug abuse/misuse (n=308, 
74.0%) and advanced paternal age (n=275, 66.1%) were 
most indicated for lifestyle-related OS testing (Fig. 2B).
3. Indication for antioxidant therapy
A total of 1,260 (94.9%) responded to the question 
on the prescription of AOX for the treatment of male 
infertility. Here, a high percentage (n=1,078, 85.6%) of 
participants recommend AOX as a therapeutic option 
in the management of male infertility, either routinely 
(n=550, 43.7%) or for specific groups of patients (n=528, 
41.9%) (Table 3: a). Of those participants who did not 
use OS testing as a part of male infertility evaluation 
(n=857), a high percentage (n=679, 79.2%) reported pre-
scribing AOX treatment.
A total of 1,039 out of 1,078 (96.4%) responded to the 
multiple option question on the clinical conditions for 
which AOX-based therapy was prescribed. Here, the 
most common clinical conditions for which AOX-based 
therapy were prescribed were risk factors for OS (such 
as obesity, age, smoking) (n=707, 68.0%), idiopathic oli-
goasthenoteratozoospermia (n=659, 63.4%), UMI (n=651, 
62.6%), isolated asthenozoospermia (n=629, 60.5%) and 
teratozoospermia (n=501, 48.2%) (Table 3: b).
A total of 1,039 participants responded to the ques-
tion on the duration of AOX treatment of male infer-
tility. Here, the majority of the participants recommend 
AOX treatment for a duration of 3 months (n=454, 
43.7%) or up to six months (n=401, 38.6%) (Table 3: c).
Furthermore, the survey results revealed that 584 
participants out of 1,039 (56.2%) who responded to this 
question treat 25%–75% of their patients with AOX 
(Fig. 3). A total of 1,039 participants responded to the 
question on the preference of AOX used in clinical 
practice. Here, the most commonly prescribed indi-
vidual AOX were zinc (n=753, 70.9%), vitamin E (n=717, 
n=69.0%), L-carnitine (n=706, 67.9%) and Co-enzyme 
Q10 (n=675, 65.0%) (Table 4).
A total of 708 participants were familiar with di-
etary AOX supplements, while 688 (97.2%) responded 
to the question on the top 10 most common commercial 
Others 2.8%
8-hydroxy-2'-deoxyguanosine 1.0%
Total antioxidant capacity 1.2%
Malondialdehyde 1.7%
Chemiluminescence assay 2.2%







Fig. 1. Tests of oxidative stress that are commonly ordered by partici-
pants in the evaluation of male infertility. 






ART management: IUI, IVF and/or ICSI
Genital tract infection ( leukocytospermia)e.g.,
Routine assessment in semen analysis
Paternal smoking or alcohol consumption or drug abuse/misuse
Advanced paternal age
Exposure to high temperature working environments
Paternal exposure to endocrine disrupting compounds













































Fig. 2. Indication for oxidative stress testing based on (A) clinical conditions and (B) lifestyle risk factors. SDF: sperm DNA fragmentation, ART: as-
sisted reproduction techniques, IUI: intrauterine insemination, IVF: in vitro fertilization, ICSI: intracytoplasmic sperm injection.
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dietary AOX supplements (Table 5). While 177 partici-
pants did not recommend the AOX treatment, 1,039 
participants recommended it mostly based on the sci-
entific evidence (n=718, 69.1%) and personal experience 
(n=616, 59.3%) (Table 6).
Participants testing for seminal OS and prescrib-
ing AOX, respectively, were further analyzed based 
on their age, geographical origin, experience and the 
training in the field of male infertility. The partici-
pants using the seminal OS markers during evaluation 
of male infertility were not influenced by their age or 
years of experience in the field (Table 7: a). Conversely, 
the geographic origin significantly influenced this de-
cision (p<0.001), with 53.2% of respondents from Asia 
opting for no testing (Fig. 4). Participants who had re-
ceived a specific training in male infertility were more 
Table 3. Indications for AOX therapy 
SN Indications for AOX therapy Self-reported responses
A (n=1,260) Prescription of the antioxidants for the treatment of male infertility
No, I never do so 182 (14.4)
Yes, but only for specific groups of patients 528 (41.9)
Yes, I routinely do so 550 (43.7)
Total 1,260 (100)
B (n=1,039) Clinical conditions treated
Risk factors for oxidative stress (obesity, age, smoking) 707 (68.0)
Idiopathic oligoasthenoteratozoospermia 659 (63.4)
Unexplained infertility 651 (62.6)
Isolated asthenozoospermia 629 (60.5)
Isolated teratozoospermia 501 (48.2)
Isolated oligozoospermia 479 (46.1)
Varicocele 429 (41.3)
Increased SDF 377 (36.3)




Altered seminal oxidative stress markers 7 (0.7)
Genital tract infection/inflammation 7 (0.7)





Indefinitely, until achieving conception 74 (7.1)
Values are presented as number (%). 
(A) Prescription of AOX in clinical management of male infertility, (B) clinical conditions treated (percentage calculated based on the total number 
of participants answering this multiple option question), and (C) duration of treatment.









Fig. 3. Percentage of patients recommended for AOX treatment by 
the participants to the survey. AOX:  antioxidant.
Ashok Agarwal, et al: Antioxidant Use in Male Infertility
477www.wjmh.org
likely to order OS testing (n=378 out of 448), although 
interestingly the majority of participants chose no test-
ing (n=626 out of 857) (p<0.001) (Fig. 4). With respect to 
prescribing AOX, the percentage of participants who 
recommended AOX was significantly related to the 
participant’s age (p<0.001), geographic origin (p<0.004), 
experience or training in male infertility (p<0.001) 
(Table 7: b, Fig. 5).
The perception of AOX treatment in clinical practice 
from the participants point of view
A total of 1,152 participants out of 1,327 (86.8%) re-
sponded to the question on the strength of the evidence 
for AOX use in male infertility. Here, more than half 
of the participants considered the evidence supporting 
AOX use in clinical practice as modest (52.3%), that is 
a score of four in a scale where 5 was strong, while the 
remaining practitioners were divided between “the evi-
dence supporting its use is strong” (19.7%) and “no good 
evidence supporting its use” (22.2%) (Table 8).
A total of 1,172 out of 1,327 (88.3%) participants re-
sponded to the multiple response question on the limi-
tations of AOX use. Here, the most important reasons 
for limiting its use were cost (n=611, 52.1%), duration of 
treatment which could postpone other treatments (such 
as assisted reproduction techniques [ART]) (n=528, 
45.0%), and low adherence of patients to the therapy 
(n=323, 27.6%).
A total of  1,172 out of  1,327 (88.3%) participants 
responded to the multiple response question on the 
most appropriate outcomes to be evaluated after AOX 
treatment. Here, survey results indicated standard se-
men parameters (n=648, 55.3%), live birth rate (n=644, 
54.9%), SDF (n=576, 49.1%) and clinical/ongoing preg-
nancy rate (n=555, 47.3%) as possible endpoints for the 
evaluation of AOX efficacy.
A total of  1,172 out of  1,327 (88.3%) participants 
responded to the multiple response question on the 
development of clinical guidelines. This was favoured 
by most of the participants (96.3%), who considered it 
either as much needed (n=607, 51.8%) and/or helpful 
(n=521, 44.5%) (Table 8).
DISCUSSION
AOX therapy has long been considered as an appeal-
ing treatment modality for male infertility [28]. The 
reasons for the interest and use of AOX are multiple. 
AOX supplements are easily accessible as over the 
counter products, are relatively inexpensive, and have 
few side effects. Importantly, they can potentially re-
verse seminal OS which is believed to be a common 
pathophysiology linking multiple etiologies with male 
Table 4. Most commonly prescribed individual antioxidants for the 





Vitamin E 717 (69.0)
L-carnitine 706 (67.9)
Co-enzyme Q10 675 (65.0)
Vitamin C 604 (58.1)
Selenium 566 (54.5)
Folic acid (vitamin B9) 437 (42.1)
L-arginine 422 (40.6)
Vitamin D 309 (29.8)
N-acetyl cysteine 271 (26.1)
Combination of vitamins with carnitine 266 (25.6)
Vitamin A or relevant carotenes 242 (23.3)
Combination of vitamins C and E 221 (21.3)
Lycopene 220 (21.2)
Methylcobalamin (vitamin B12) 161 (15.5)
Riboflavin (vitamin B2) 149 (14.3)
Thiamine (vitamin B1) 147 (14.1)
Glutathione 140 (13.5)
Acetyl carnitine 138 (13.3)
Herbal antioxidants or products 128 (12.3)
Pentoxifylline 128 (12.3)
Pyridoxal-5-phosphate (vitamin B6) 119 (11.4)
Methylfolate 104 (10.0)
Biotin 102 (9.8)
Alpha-lipoic acid 79 (7.6)
Docosahexanoic acid (DHA) 77 (7.4)
Pantothenic acid (vitamin B5) 67 (6.4)




Vitamin K2 29 (2.8)
Chelated copper 22 (2.1)
Para-aminobenzoic acid (PABA) 22 (2.1)
Methylsulfonylmethane (MSM) 17 (1.6)
Phosphatidylcholine 15 (1.4)
Values are presented as number (%*). 
*Percentage was calculated based on the total number of partici-
pants (n=1,039) who answered this multiple option question.
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infertility [7]. However, there is little information 
available on the use of OS testing and AOX in clinical 
practice.
1. Oxidative stress testing in clinical practice
The survey results show that there is a relatively 
low proportion of participants conducting OS testing. 
This may be due to lack of consensus on appropriate 
tests and their clinically relevant cut-off values, and 
an absence of standardization of laboratory techniques 
[29]. Although sensitivity and specificity of various 
tests have been published, they remain variable, non-
standardized and without general diagnostic recom-
mendations [30,31]. Furthermore, many tests for OS are 
expensive, may be time-consuming, often require spe-
cialized training, and are therefore not readily avail-
able in clinical and diagnostic laboratories [29]. This 
may be particularly apparent in developing countries, 
where empirical prescription of AOX in suspected cases 
of OS may represent a less expensive alternative to 
advanced testing. Interestingly, though 85.6% (Table 3: 
a) of participants reported the use of AOX, either rou-
tinely (43.7%) or in specific patient groups (41.9%), the 
majority (65.7%) (Table 2) did not use OS testing in the 
assessment of their patients. This may be due to the 
fact that the prescription of AOX is likely cheaper and 
more convenient compared to the assessment of OS. 
However, this is a potential clinical concern, as without 
identifying men with OS and monitoring ROS levels 
during therapy, there exists the risk of inducing reduc-
tive stress due to excessive AOX therapy. Reductive 
stress can be as damaging as OS [25,32] and may itself 
be a cause of male infertility [33].
Numerous testing methods have been developed over 
the past few decades to determine OS or measure ROS 
in semen [29]. However, these tests currently have lim-
ited practical use and are mostly limited to research [34]. 
This is reflected in the current survey results, with 
chemiluminescence detection being used by only 2.2% 
of participants (Fig. 1). Indirect tests determine the im-
Table 6. Reasons selected by clinicians to recommend (n=1,039) or not recommend (n=177) the use of AOX in treatment of male infertility 
Reasons to recommend Self-reported responses Reasons not to recommend Self-reported responses
Scientific evidence 718 (69.1) Lack of scientific evidence   85 (48.0)
Personal experience 616 (59.3) Unfamiliar with the field   76 (42.9)
Relevant knowledge 271 (26.1) Personal experience 14 (7.9)
Advice from peers 235 (22.6) Other   23 (13.0)
Trained by someone that uses them 222 (21.4)
Patient request/feedback 185 (17.8)
Values are presented as number (%*).
AOX: antioxidants.
*Percentage was calculated based on the total number of participants who answered these multiple option questions.
Table 5. Top 10 most common commercial dietary AOX supplements recommended for treatment of male infertility 
Product Company City, Country Value
Proxeed Plus Alfasigma Milan, Italy 254 (36.9)
Profertil LENUS Pharma GesmbH Vienna, Austria 179 (26.0)
Fertilaid Fairhaven Health Bellingham, WA, USA 135 (19.6)
Fertilix Fertilix Hasbrouck Heights, NJ, USA 106 (15.4)
Conception Men Eu Natural Henderson, NV, USA 61 (8.9)
Orthomol Plus Orthomol Langenfeld, Germany 56 (8.1)
Conceive Plus Sasmar Inc. Chicago, IL, USA 55 (8.0)
FH Pro for Men Fairhaven Health Bellingham, WA, USA 40 (5.8)
Coast Science Coast Science San Diego, CA, USA 39 (5.7)
Conception XR Theralogix Rockville, MD, USA 34 (4.9)
Values are presented as number (%*).
AOX: antioxidants. 
*Percentage was calculated based on the total number of participants (n=688) who answered this multiple option question.
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pact of OS on lipids, proteins or DNA, or determination 
of conditions closely associated with OS, and therefore 
do not include direct measures of ROS or AOX. These 
include assays for malondialdehyde (MDA), thiobar-
bituric acid (TBARS) or 4-hydroxynonenal (4-HNE) as 
mutagenic by-products of lipid peroxidation, 8-hydroxy-
2-deoxyguanosine (8-OHdG) as a marker of damage to 
DNA, and other assessments of SDF [5,34-36].
Table 7. Patterns of oxidative stress testing and prescription of AOX according to the participants’ age, geographic origin, experience (in years) 
and training in male infertility 
Seminal oxidative stress testing as a part of male infertility evaluation
Testing for  
oxidative stress
Age of practitioner (y)
25–34 35–44 45–54 55–64 ≥65 Total responses p-value*
Do not test OS markers 130 (15.2) 316 (37.1) 196 (23.0) 133 (15.6) 78 (9.1) 853 (100) NS
Do test OS markers   67 (15.0) 139 (31.0) 112 (25.1)   78 (17.5)   51 (11.4) 447 (100)
Geographic macro-areas
Africa Asia Australia Europe
North  
America
South America Total responses p-value*
Do not test OS markers 108 (12.6) 454 (53.2) 13 (1.5) 111 (13.0) 41 (4.8) 127 (14.9) 854 (100) <0.001
Do test OS markers 39 (8.7) 148 (33.1) 16 (3.6)   93 (20.8) 16 (3.6) 135 (30.2) 447 (100)
Years of experience
<2 2–5 5–10 >10 Total responses p-value*
Do not test OS markers 63 (7.3) 117 (13.6) 155 (18.2) 522 (60.9) 857 (100) NS
Do test OS markers 32 (7.1)   60 (13.4)   77 (17.2) 279 (62.3) 448 (100)
Specific training in male infertility
No training  
in male infertility
Yes, as a specific  
training program (fellowship)
Yes, as part of my specific  
training (residency)
Total responses p-value*
Do not test OS markers 231 (26.9) 216 (25.3) 410 (47.8) 857 (100) <0.001
Do test OS markers   70 (15.6) 171 (38.2) 207 (46.2) 448 (100)
Prescription of antioxidants to treat male infertility
Prescription of AOX
Age of practitioner (y)
25–34 35–44 45–54 55–64 ≥65 Total responses p-value*
Do not prescribe AOX   42 (23.2)   59 (32.6)   38 (21.1) 18 (9.9)     24 (13.2)    181 (100) <0.001
Do prescribe AOX 146 (13.6) 377 (35.1) 263 (24.5) 185 (17.2) 103 (9.6) 1,074 (100)
Geographic macro-areas
Africa Asia Australia Europe
North  
America
South America Total responses p-value*
Do not prescribe AOX 10 (5.5) 100 (55.2)   2 (1.2)   28 (15.5) 14 (7.7)   27 (14.9)    181 (100) <0.004
Do prescribe AOX 129 (12.0) 480 (44.6) 27 (2.5) 171 (15.9) 41 (3.8) 227 (21.2) 1,075 (100)
Years of experience
<2 2–5 5–10 >10 Total responses p-value*
Do not prescribe AOX   28 (15.3)   28 (15.3)   33 (18.2)   93 (51.2)    182 (100) <0.001
Do prescribe AOX 64 (5.9) 139 (12.9) 190 (17.6) 685 (63.6) 1,078 (100)
Specific training in male infertility
No
Yes, as a specific training  
program (fellowship)
Yes, as part of my specific  
training (residency)
Total responses p-value*
Do not prescribe AOX   80 (43.9)   39 (21.5)   63 (34.6)    182 (100) <0.0001
Do prescribe AOX 211 (19.6) 334 (31.0) 533 (49.4) 1,078 (100)
Values are presented as number (%).
AOX: antioxidant, OS: oxidative stress, NS: not significant. 
*p-value obtained by chi-square test.
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OS is a well-recognized cause of SDF [29,37]. Recently, 
Agarwal et al [38] proposed clinical guidelines for SDF 
testing and showed that there is strong evidence that 
varicocele, IMI, UMI and a detrimental lifestyle are as-
sociated with increased OS, and hence necessitate SDF 
assessment. This is supported by the survey results, 
where SDF assessment was most strongly reported for 
use as a marker of OS by 53.4% of respondents (Fig. 1). 
SDF has been found to correlate positively with MDA, 
and negatively with superoxide dismutase and gluta-
thione peroxidase, in semen samples of infertile men 
[39]. This correlation has also been reported in males 
with subclinical, normozoospermic, asthenozoospermic 
and oligozoospermic varicocele [40]. Linear correlations 
between SDF and seminal OS with increasing paternal 
age [41] have also been noted. However, it is suggested 
that both SDF and another measure of OS should be 
used in the evaluation of infertile men [39]. This is 
supported by Homa et al [42], who suggests that nei-
ther chemiluminescence nor ORP should be used alone 
to determine OS. This may explain a high proportion 
(31.3%) of participants reporting the use of more than 
one assessment for OS. Although there are numerous 
SDF testing methods for diagnostic and research use, 
with terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL), sperm chromatin 
structure analysis (SCSA), and sperm chromatin dis-
persion (SCD) being most commonly used, these tests 
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Fig. 5. Antioxidant prescription based on 
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The survey results show that 6.3% of participants 
used ORP for assessment of OS, third most frequent 
after SDF and combination testing (Fig. 1). The ORP 
has been introduced recently to determine seminal OS 
directly as an electrochemical measurement using the 
male infertility oxidative system (MiOXSYS; Aytu Bio-
science, Englewood, CO, USA) [31,45]. Increased seminal 
ORP, indicative of OS, has been reported to correlate 
positively with SDF when normalized with sperm con-
centration and motile sperm concentration [46].
Important clinical indications for OS testing in-
cludes varicocele, genitourinary tract infections, obe-
sity, diabetes, IMI and UMI [6,35]. The most commonly 
reported clinical reason for OS testing in this survey 
was abnormal semen parameters (59.9% of participants 
that assess OS, Fig. 2A). This is consistent with the 
literature, where asthenozoospermia, teratozoospermia, 
leukocytospermia and increased seminal viscosity have 
each been suggested as potential surrogate markers of 
seminal OS [47-49]. Abnormal semen parameter(s) are 
also reflected in the diagnosis of IMI, defined as hav-
ing one or more abnormal semen parameter(s) without 
identifiable cause [6]. IMI was reported to be an indica-
tion for OS testing by a further 44.2% of participants 
Table 8. Perception of AOX treatment in clinical practice from the point of view of the participants
SN Survey questions Self-reported responses
A Strength of the evidence for AOX use in male infertility (n=1,152)
The evidence supporting its use is modest 602 (52.3)
There is no good evidence supporting its use 256 (22.2)
The evidence supporting its use is strong 227 (19.7)
Do not know or not applicable to my practice 49 (4.3)
There is evidence against its use 18 (1.5)
B Limitations for AOX use
Cost 611 (52.1)
Long-time therapy postponing definitive treatment (e.g., ART) 528 (45.0)
Low treatment adherence 323 (27.6)
Not effective 291 (24.8)
Side effects 44 (3.7)
Uncertain benefit 16 (1.4)
Lack of good evidence supporting their use 14 (1.2)
Other 11 (0.9)
No good evidence supporting its benefit 7 (0.6)
They are effective only in specific patients’ subgroups 4 (0.3)
C Endpoints to be evaluated after AOX treatment
Standard semen parameters 648 (55.3)
Live birth rate 644 (54.9)
Sperm DNA fragmentation (SDF) 576 (49.1)
Clinical/ongoing pregnancy rate 555 (47.3)
Reactive oxygen species (ROS) 345 (29.4)
Miscarriage rate 278 (23.7)
Oxidation-reduction potential (ORP) 217 (18.5)
Total antioxidant capacity (TAC) 173 (14.7)
Other 5 (0.4)
D The necessity of clinical practice guidelines
Helpful, although more well-designed clinical trials would be needed 521 (44.5)
Much needed, as clear guidelines on the topic are lacking 607 (51.8)
Not necessary, as antioxidants are already proved to be effective 19 (1.6)
Not necessary, as antioxidants are ineffective 25 (2.1)
Values are presented as number (%).
SN: serial number, AOX:  antioxidant, ART: assisted reproductive technology.
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that assess OS (Fig. 2A). The condition of UMI, defined 
as patients being infertile despite having normal se-
men parameters, was the second most reported clinical 
indication for testing (55.8% of participants that assess 
OS, Fig. 2A). Importantly, OS is reported in 11%–78% 
of males diagnosed with UMI and 30%–80% of cases 
of IMI [50,51]. For the latter, the term MOSI has been 
introduced for males with IMI and who are positive for 
seminal OS [6].
Numerous lifestyle factors are known to increase the 
risk for male infertility and abnormal semen param-
eters. These include alcohol, tobacco and recreational 
drug use, increased heat exposure to the genitals, expo-
sure to endocrine disrupting chemicals, and radiation 
[52-54]. Detrimental lifestyle factors are also associated 
with increased OS as a common underlying media-
tor of male infertility [52]. This reflects in the results 
of this survey in which there was a relatively even 
spread across these risk factors as indications for OS 
testing (Fig. 2B).
2. Antioxidant use in clinical practice
This survey confirms the widespread use of AOX to 
treat men with infertility. Almost half (43.7%) of clini-
cians routinely propose AOX therapy to all patients, 
while another 41.9% offer it to men with specific in-
dications (Table 3: a). More than half the respondents 
(56.2%) stated that 25%–75% of their patients received 
AOX therapy (Fig. 3). Even the vast majority (80%) of 
those who did not test for OS or SDF still prescribed 
AOX therapy. There are numerous possible reasons un-
derlying this practice. Firstly, there is no specific ther-
apy for most men with infertility and even in cases 
with a correctable male factor the use of AOX therapy 
may be beneficial. Secondly, there is widespread avail-
ability of “over the counter” AOX both individually 
and/or in combination, with 55.3% of respondents be-
ing familiar with dietary AOX supplements (Table 5). 
Thirdly, AOX have been widely represented as having 
numerous health benefits with a good safety profile. 
Thus, both clinicians and patients perceive AOX to be 
safe. There is also relative ease of use, where taking 
AOX tablets is preferable to more invasive procedures 
like varicocele surgery or ART. Lastly, considering 
patient demographics, 70.1% of the respondents were 
either from Asia or South America (Fig. 4). In both 
these regions, there is a long history of use of natural 
medicines, which possibly makes this patient popula-
tion more compliant with long-term empirical medical 
therapy.
On the other hand, the study also identified several 
potential inconsistencies to the use of AOX. The dura-
tion of therapy recommended was generally either for 
3 months (reflecting the average length of the sper-
matogenesis process) or 6 months, while some give it 
indefinitely until pregnancy (Table 3: c). Despite rela-
tive ease of taking tablets daily, patient compliance 
can be a challenge when the duration of treatment is 
long, especially since infertile couples usually want a 
rapid positive result. Furthermore, this may delay the 
utilization of more effective therapies, such as ART, 
while the couple awaits the unpredictable outcome of 
AOX therapy. Although relatively cost-effective, AOX 
combinations containing compounds like L-carnitine 
and Co-enzyme Q10 can be expensive, and when used 
for a long duration, may prove to be costly for economi-
cally constrained patients. The survey further showed 
that there is no consensus on what the outcome mea-
sure should be to evaluate the benefits obtained from 
AOX therapy. While 55.3% of participants suggested 
improvement in semen parameters, there was an equal 
number who felt that the end point should be live 
birth rate (Table 8). Other end-points suggested were 
reduction in SDF or clinical pregnancy rates (Table 8). 
This diversity of opinion causes difficulty in conduct-
ing good clinical studies on AOX therapy that would 
gain widespread acceptance. Significant diversity was 
found in the therapies used by the respondents with 36 
different AOX being listed (the top 10 AOX are listed 
in Table 5). It is in this context that there is a clear 
need for evidence-based guidelines for AOX treatment 
in male infertility.
3. Evidence based medicine
In the modern age, clinical care has shifted towards 
the practice of evidence-based medicine (EBM), defined 
as “the conscientious, explicit and judicious use of cur-
rent best evidence in making decisions about the care 
of individual patients” [55]. EBM incorporates the clini-
cians’ experience and patient values with high quality 
medical research aiming to optimize clinical decision 
making. Amongst survey participants, AOX treatment 
was recommended mostly based on scientific evidence 
(69.1%) and personal experience (59.3%) (Table 6), re-
flecting some adherence to EBM guidelines.
Most of the clinical evidence investigating the ef-
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ficacy of AOX therapy on male fertility comes from 
three published reviews by the Cochrane library in 
2011, 2014, and 2019 [20,56,57]. The last update included 
61 randomized clinical trials (RCTs) and collectively 
reported that AOX therapy for the treatment of male 
infertility is associated with a significant increase 
in pregnancy and live birth rates [20]. However, the 
quality of the reported evidence was low, which was 
attributed to the small study size and extensive het-
erogeneity across the included studies, with multiple 
AOX regimens, varied doses and different treatment 
durations. Moreover, the primary treatment groups 
were different. Some AOX trials were using it to boost 
natural or intrauterine insemination (IUI) conception, 
where others were aimed at augmenting in vitro fer-
tilization-intracytoplasmic sperm injection (IVF-ICSI) 
outcomes in male factor infertility. As the latter is 
more reliant on improving sperm DNA quality, rather 
than motility or count, it is understandable that AOX 
therapy may be more advantageous in an IVF setting 
than in natural conception. Finally, many trials did 
not screen for OS and hence may include subjects who 
may not have OS and therefore would not benefit from 
AOX therapy.
Recently Agarwal et al [27] published clinical guide-
lines on the utility of AOX in the treatment of male 
infertility that were based on a systematic review and 
critical analysis of the evidence. The authors included 
97 articles in their systematic review that were evalu-
ated using multiple quality scores. They found that the 
majority of low-quality studies reported a significant 
improvement in semen parameters (85.7%) and sperm 
function tests (89.6%) following AOX therapy. Further-
more, 78.6% of low-quality studies showed a positive 
effect for AOX treatment on reproductive outcomes. 
While a significant effect was not detected among 
high-quality studies investigating the impact of AOX 
therapy on male fertility potential, 65% of low-quality 
studies investigating semen parameters, 58.3% sperm 
function and 60% reproductive outcomes, showed a pos-
itive effect. Overall, positive effects in semen param-
eters and sperm function following AOX therapy were 
reported by both the low- and high-quality studies for 
men with varicocele, abnormal semen parameters, IMI 
and UMI. This is supported by proteomic evidence that 
AOX therapy enhances AOX defence mechanisms at 
the subcellular level and is associated with overexpres-
sion of sperm proteins that are essential for the fertil-
ization process [58].
Despite the reported data, recent practice statements 
published by international societies have showcased 
more negative views towards the use of AOX as a 
treatment modality for infertile men. The European 
Association of Urology (EAU) states that “No clear 
recommendation can be made for treatment of patients 
with idiopathic infertility using antioxidants, although 
antioxidant use may improve semen parameters (weak 
strength rating)” [59]. The American Society for Repro-
ductive Medicine (ASRM) recommended that “clinicians 
should counsel patients that the benefits of supple-
ments (e.g., antioxidants, vitamins) are of questionable 
clinical utility in treating male infertility. Existing 
data are inadequate to provide recommendation for 
specific agents to use for this purpose. (Conditional 
Recommendation; Evidence Level: Grade B)” [60]. How-
ever, the extensive research that has been published 
on the study of AOX certainly warrants the formula-
tion of new specific guidelines on the topic that would 
consider the utility of OS diagnostic testing, AOX type, 
dose and duration, and the clinical indications for AOX 
therapy.
4. Limitations of online survey
It is important to highlight some sources of bias 
which might have affected the collection of results 
through the online survey [61]. The survey link was 
shared around the world through the personal and 
professional society contacts of the experts associated 
with this study. The official and unofficial channels 
used might have created a selection bias, leading to 
an over- or under- representation of some countries in 
the results. Secondly, participants routinely prescrib-
ing AOX may have been more likely to fill out the 
survey, leading to participation bias [62]. There is also 
the impossibility to calculate a response rate, as it was 
not possible to keep track of the number of individu-
als who were given the opportunity to participate in 
the survey [63]. The length of the survey as well as 
the extensive number of questions might also have 
discouraged participants from completing it, leading to 
incomplete results.
Several strategies were put in place to reduce the 
bias of the results. First, the survey was carefully cre-
ated, with several rounds of revisions by experts in the 
field. The aim was to collect reliable observations, by 
reducing the possibility of ambiguous, uncertain data 
https://doi.org/10.5534/wjmh.210025
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or misinterpretation [64]. The questionnaire was anon-
ymous, to reduce the risk of desirability bias, where 
participants provide the feedback which is hypothet-
ically-preferred [65]. The English language was also 
revised to make questions clearer and easily under-
standable for non-English speaking participants or for 
participants who spoke English as a second language. 
Furthermore, the online nature of the survey made it 
possible to reach a larger audience. Hence, it is reason-
able to speculate that our results may represent a reli-
able and accurate global picture of the use of AOX in 
clinical practice for male infertility treatment.
5. Experts’ opinion based on AOX survey results
This survey reports the opinions of 1,327 healthcare 
practitioners from around the world regarding the 
utility of AOX therapy for male infertility in clinical 
practice. Despite the recently published recommenda-
tions from international societies, including ASRM and 
EAU [60], 85.4% of respondents believe that AOX are a 
useful treatment option for men with infertility, with 
69.1% of them basing their decision on scientific evi-
dence in support for AOX use (Table 6). Indeed, such 
evidence exists, although the studies supporting the 
use of AOX are small and heterogeneous. As such, the 
question remains whether the quality of evidence is 
sufficient to justify the use of AOX therapy for male 
infertility, mainly when considering that it has a very 
low risk of side effects. High-quality evidence is diffi-
cult to obtain practically and is not currently available. 
The possibility of conducting placebo-controlled RCTs 
of AOX therapy is limited by the fact that patients can 
buy AOX over the counter at the local pharmacy or 
supermarket. As such, we may never be in a position to 
gather Level 1 evidence. In the meantime, clinical prac-
tice recommendations based on the currently available 
best evidence seems the most reasonable approach. 
Infertility is a unique medical condition which, despite 
the tremendous progress in its management, still suf-
fers from many unknowns. Conception results from 
the highly complex interplay between a spermatozoon 
and an oocyte and is influenced by numerous variables, 
many of which are yet to be discovered. This is the rea-
son why infertility is still unexplained in up to 30% of 
couples [50]. Furthermore, male factors causing an im-
pairment in semen quality are unknown in about 50% 
of cases, and hence the term IMI [6]. AOX are dietary 
supplements that generally have a good safety profile 
and are supported by low-quality evidence showing 
that a positive effect on semen quality and reproduc-
tive function can be expected following treatment. 
Moreover, recent evidence revealed that when AOX 
are used for specific clinical indications (IMI and UMI), 
the improvement in semen quality has been shown by 
a high quality of evidence [27]. For these reasons, we 
advocate the use of AOX in clinical practice, provided 
that the following criteria are met:
1)  Laboratory evidence of seminal OS. Testing for OS 
is recommended to identify the appropriate candi-
dates for AOX therapy.
2)  Consider treatment for a duration of 3–6 months, 
which is a sufficient intervention period to obtain 
a measurable impact on spermatogenesis.
3)  Avoid excessive use of AOX, in high doses or for a 
prolonged duration, to avoid iatrogenic infertility 
due to reductive stress [33].
4)  Finally, there is no consensus on the choice of 
AOX to be used. Based on physiological consider-
ations, it would seem appropriate to use a combi-
nation of AOX that act on different physiological 
processes of the spermatozoa, such as preservation 
of energy metabolism, and improvement of sperm 
maturation and function, as well as providing pro-
tection from ROS.
5)  AOX therapy should not be used to replace any 
other kind of treatment but should instead be seen 
as a viable synergistic option.
CONCLUSIONS
While the scientific evidence is of low quality, use 
of AOX in the management of infertile men is a com-
mon practice. Health care providers differ in their ap-
proach to AOX therapy, including evaluation of the OS 
status prior to commencing the treatment, the clinical 
indications for treatment, the AOX dose, duration, for-
mulation, the end-point to be analysed, the follow up 
period, etc. Results from the present survey once again 
highlight the necessity for clinical practice guidelines 
on the use of AOX therapy in the management of the 
infertile male.
ACKNOWLEDGEMENTS
Authors are thankful to the artists from the Cleve-
Ashok Agarwal, et al: Antioxidant Use in Male Infertility
485www.wjmh.org
land Clinic’s Center for Medical Art & Photography for 
their help with the illustrations. The study was sup-
ported by the American Center for Reproductive Medi-
cine, Cleveland Clinic.
The authors are thankful to the following societies 
and journals for promoting this online survey through 
the efforts of their members listed below:
1.  African Network and Registry for ART (Hassan N. 
Sallam, MD, PhD, Egypt)
2.  African Regional Reproductive, Maternal, Neo-
natal and Child Health WHO Task Force, Ibadan, 
Nigeria (Hassan N. Sallam, MD, PhD, Egypt)
3.  Algerian Fertility Society (Amina Oumeziane, MD, 
PhD, Algeria; Hassan N. Sallam, MD, PhD, Egypt)
4.  American College of  Embryology (Dmitri 
Dozortsev, MD, USA)
5.  Andrologia (Ralf Henkel, PhD, UK)
6.  Asia Pacific Society of Sexual Medicine (Hyun Jun 
Park, MD, South Korea)
7.  Association for Fertility and Reproductive Health 
(Hassan N. Sallam, MD, PhD, Egypt)
8.  Association of Reproductive and Clinical Scientists 
(Ralf Henkel, PhD, UK)
9.  Brazilian Society of Urology (Rafael F. Ambar, 
MD, Brazil)
10.  Brazilian Society of Assisted Reproduction (Edson 
Borges, MD, Brazil)
11.  Cameroonian Syndicate of Private doctors (Hassan 
N. Sallam, MD, PhD, Egypt)
12. CECOS, Italy (Giovanni M. Colpi, MD, Italy)
13.  Collège Marocain de Fertilité (Jamal Fikri, MD, 
PhD, Morocco; Giovanni M. Colpi, MD, Italy)
14.  Egyptian Society of Andrology (Taymour Mostafa, 
MD, Egypt; Mohamed Arafa, MD, Qatar)
15.  Egyptian Foundation for Reproductive Medicine 
and Embryology (Medhat Amer, MD, Egypt)
16.  ESHRE Certification for Reproductive Endoscopic 
Surgery (Hassan N. Sallam, MD, PhD, Egypt)
17.  European Society for Gynaecological Endoscopy 
(Hassan N. Sallam, MD, PhD, Egypt)
18.  Société d’andrologie de langue française (Edouard 
Amar, MD, France)
19.  GIERAF (Groupe interAfricain d’étude, de re-
cherche et d’application sur la fertilité) (Hassan N. 
Sallam, MD, PhD, Egypt)
20.  Hong Kong Medical Association (Hyun Jun Park, 
MD, South Korea)
21.  International Society of IVF (Hassan N. Sallam, 
MD, PhD, Egypt)
22.  International Society of Sexual Medicine (Rafael 
Ambar, MD, Brazil)
23.  Iranian Society for Reproductive Medicine (Mo-
hammad Ali Sadighi Gilani, MD, Iran)
24.  Iranian Urological Association (Mohammad Ali 
Sadighi Gilani, MD, Iran; Mohammad-Reza Moe-
in, MD, Iran)
25.  Japan Society of Assisted Reproduction (Yoshi-
haru Morimoto, MD, Japan)
26.  Lebanese Urology Society (Ahmad Majzoub, MD, 
Qatar)
27.  Mediterranean Society for Reproductive Medicine 
(Hassan N. Sallam, MD, PhD, Egypt)
28.  Mexican Association for Reproductive Medicine 
(Israel Maldonado, PhD, Mexico)
29.  Middle East Fertility Society (Hassan N. Sallam, 
MD, PhD, Egypt)
30.  Moroccan Fertility Society (Hassan N. Sallam, 
MD, PhD, Egypt)
31.  Red Latino Americana de Reproducción Asistida 
(Rafael F. Ambar, MD, Brazil)
32.  Royal College of Obstetricians and Gynaecologists 
in Kuwait (Hassan N. Sallam, MD, PhD, Egypt)
33.  Saudi Endometriosis Group (Hassan N. Sallam, 
MD, PhD, Egypt)
34.  Saudi Fertility Group (Hassan N. Sallam, MD, 
PhD, Egypt)
35.  Saudi Society for Obstetrics and Gynecology (Has-
san N. Sallam, MD, PhD, Egypt)
36.  Sociedad Argentina de Andrología (Rafael Am-
bar, MD, Brazil)
37.  Société de la Médecine de la Reproduction (Ed-
ouard Amar, MD, France)
38.  Societa' Italiana di Riproduzione Umana (Giovan-
ni M. Colpi, MD, Italy)
39.  Spanish Society of Andrology (Juan Alvarez, MD, 
Spain)
40.  Togolese Fertility Society (Hassan N. Sallam, MD, 
PhD, Egypt)
41.  Turkish Urological Society (Giovanni M. Colpi, 
MD, Italy)
42.  Urological Society of Australia and New Zealand 
(USANZ) (Hyun Jun Park, MD, South Korea)
43.  World Congress of IVF 2021 (Hassan N. Sallam, 
MD, PhD, Egypt)





The authors have nothing to disclose.
Author Contribution
Conceptualization: AA. Data curation: MKPS, RF. Methodol-
ogy: MKPS, RF. Project administration: AA, MKPS. Writing–
original draft: AA, MKPS, RF, KL, DD, AM, RS, NT, NP, EK. 
Writing–review & editing: all authors.
Supplementary Material
Supplementary material can be found via https://doi.
org/10.5534/wjmh.210025.
REFERENCES
1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique 
view on male infertility around the globe. Reprod Biol Endo-
crinol 2015;13:37.
2. Agarwal A, Baskaran S, Parekh N, Cho CL, Henkel R, Vij S, et 
al. Male infertility. Lancet 2021;397:319-33.
3. Kumar N, Singh AK. Trends of male factor infertility, an 
important cause of infertility: a review of literature. J Hum 
Reprod Sci 2015;8:191-6.
4. Fainberg J, Kashanian JA. Recent advances in understanding 
and managing male infertility. F1000Res 2019;8:F1000 Fac-
ulty Rev-670.
5. Leisegang K, Henkel R. Oxidative stress: relevance, evalua-
tion, and management. In: Rizk B, Agarwal A, Sabanegh ES Jr, 
editors. Male infertility in reproductive medicine: diagnosis 
and management. Boca Raton (FL): CRC Press; 2019;119-28.
6. Agarwal A, Parekh N, Panner Selvam MK, Henkel R, Shah R, 
Homa ST, et al. Male oxidative stress infertility (MOSI): pro-
posed terminology and clinical practice guidelines for man-
agement of idiopathic male infertility. World J Mens Health 
2019;37:296-312.
7. Kumar N, Singh AK. Reactive oxygen species in seminal 
plasma as a cause of male infertility. J Gynecol Obstet Hum 
Reprod 2018;47:565-72.
8. Agarwal A, Cho CL, Esteves SC, Majzoub A. Reactive oxygen 
species and sperm DNA fragmentation. Transl Androl Urol 
2017;6(Suppl 4):S695-6.
9. Aitken RJ. DNA damage in human spermatozoa; important 
contributor to mutagenesis in the offspring. Transl Androl 
Urol 2017;6(Suppl 4):S761-4.
10. Ali M, Martinez M, Parekh N. Are antioxidants a viable treat-
ment option for male infertility? Andrologia 2021;53:e13644.
11. Grand View Research. Dietary supplements market size, share 
& trends analysis report by ingredient (vitamins, minerals), 
by form, by application, by end user, by distribution channel, 
by region and segment forecasts, 2020 - 2027 [Internet]. San 
Francisco (CA): Grand View Research; c2020 [cited 2021 Feb 






12. Negri L, Benaglia R, Monti E, Morenghi E, Pizzocaro A, 
Levi Setti PE. Effect of superoxide dismutase supplementa-
tion on sperm DNA fragmentation. Arch Ital Urol Androl 
2017;89:212-8.
13. Arafa M, Agarwal A, Majzoub A, Panner Selvam MK, Bas-
karan S, Henkel R, et al. Efficacy of antioxidant supplementa-
tion on conventional and advanced sperm function tests in 
patients with idiopathic male infertility. Antioxidants (Basel) 
2020;9:219.
14. Nazari L, Salehpour S, Hosseini S, Allameh F, Jahanmardi F, 
Azizi E, et al. Effect of antioxidant supplementation contain-
ing L-carnitine on semen parameters: a prospective interven-
tional study. JBRA Assist Reprod 2021;25:76-80.
15. Khani B, Bidgoli SR, Moattar F, Hassani H. Effect of sesame 
on sperm quality of infertile men. J Res Med Sci 2013;18:184-
7.
16. Tartibian B, Maleki BH. Correlation between seminal oxida-
tive stress biomarkers and antioxidants with sperm DNA 
damage in elite athletes and recreationally active men. Clin J 
Sport Med 2012;22:132-9.
17. Chattopadhyay R, Yasmin S, Chakravarty BN. Effect of con-
tinuous 6 months oral antioxidant combination with univer-
sally recommended dosage in idiopathic male infertility. Int J 
Infertil Fetal Med 2016;7:1-6.
18. Keskes-Ammar L, Feki-Chakroun N, Rebai T, Sahnoun Z, 
Ghozzi H, Hammami S, et al. Sperm oxidative stress and the 
effect of an oral vitamin E and selenium supplement on se-
men quality in infertile men. Arch Androl 2003;49:83-94.
19. Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Rus-
sell JM, Cooke ID, et al. A double-blind randomized placebo 
cross-over controlled trial using the antioxidant vitamin E to 
treat reactive oxygen species associated male infertility. Fertil 
Steril 1995;64:825-31.
20. Smits RM, Mackenzie-Proctor R, Yazdani A, Stankiewicz MT, 
Jordan V, Showell MG. Antioxidants for male subfertility. Co-
chrane Database Syst Rev 2019;3:CD007411.
Ashok Agarwal, et al: Antioxidant Use in Male Infertility
487www.wjmh.org
21. Imamovic Kumalic S, Pinter B. Review of clinical trials on 
effects of oral antioxidants on basic semen and other param-
eters in idiopathic oligoasthenoteratozoospermia. Biomed 
Res Int 2014;2014:426951.
22. Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, 
Diamond MP, et al. The effect of antioxidants on male factor 
infertility: the Males, Antioxidants, and Infertility (MOXI) 
randomized clinical trial. Fertil Steril 2020;113:552-60.e3.
23. da Silva TM, Maia MCS, Arruda JT, Approbato FC, Men-
donça CR, Approbato MS. Folic acid does not improve se-
men parametrs in subfertile men: a double-blin, randomized, 
placebo-controlled study. J Bras Reprod Assist 2013;17:152-7.
24. Ménézo YJ, Hazout A, Panteix G, Robert F, Rollet J, Cohen-
Bacrie P, et al. Antioxidants to reduce sperm DNA fragmenta-
tion: an unexpected adverse effect. Reprod Biomed Online 
2007;14:418-21.
25. Panner Selvam MK, Agarwal A, Henkel R, Finelli R, Robert 
KA, Iovine C, et al. The effect of oxidative and reductive stress 
on semen parameters and functions of physiologically normal 
human spermatozoa. Free Radic Biol Med 2020;152:375-85.
26. Kuchakulla M, Soni Y, Patel P, Parekh N, Ramasamy R. A sys-
tematic review and evidence-based analysis of ingredients in 
popular male fertility supplements. Urology 2020;136:133-41.
27. Agarwal A, Leisegang K, Majzoub A, Henkel R, Finelli R, 
Panner Selvam MK, et al. Utility of antioxidants in the treat-
ment of male infertility: clinical guidelines based on a sys-
tematic review and analysis of evidence. World J Mens Health 
2021. doi: 10.5534/wjmh.200196 [Epub].
28. Majzoub A, Agarwal A. Systematic review of antioxidant 
types and doses in male infertility: benefits on semen param-
eters, advanced sperm function, assisted reproduction and 
live-birth rate. Arab J Urol 2018;16:113-24.
29. Alahmar AT. Role of oxidative stress in male infertility: an 
updated review. J Hum Reprod Sci 2019;12:4-18.
30. SharmaR, Roychoudhury S, Singh N, Sarda Y. Methods to 
measure Reactive Oxygen Species (ROS) and Total Antioxi-
dant Capacity (TAC) in the reproductive system. In: Agarwal 
A, Sharma R, Gupta S, Harlev A, Ahmad G, du Plessis SS, et 
al., editors. Oxidative stress in human reproduction: shedding 
light on a complicated phenomenon. Cham: Springer Inter-
national Publishing; 2017;17-46.
31. Agarwal A, Roychoudhury S, Bjugstad KB, Cho CL. Oxida-
tion-reduction potential of semen: what is its role in the treat-
ment of male infertility? Ther Adv Urol 2016;8:302-18.
32. Castagné V, Lefèvre K, Natero R, Clarke PG, Bedker DA. An 
optimal redox status for the survival of axotomized ganglion 
cells in the developing retina. Neuroscience 1999;93:313-20.
33. Henkel R, Sandhu IS, Agarwal A. The excessive use of antiox-
idant therapy: a possible cause of male infertility? Andrologia 
2019;51:e13162.
34. Ko EY, Sabanegh ES Jr, Agarwal A. Male infertility testing: 
reactive oxygen species and antioxidant capacity. Fertil Steril 
2014;102:1518-27.
35. Agarwal A, Leisegang K, Sengupta P. Oxidative stress in 
pathologies of male reproductive disorders. In: Preedy VR, 
editor. Pathology: oxidative stress and dietary antioxidants. 
London: Academic Press; 2020;15-27.
36. Agarwal A, Majzoub A. Laboratory tests for oxidative stress. 
Indian J Urol 2017;33:199-206.
37. Henkel R, Leisegang K. Origins of sperm DNA damage. In: 
Parekattil SJ, Esteves SC, Agarwal A, editors. Male infertility: 
contemporary clinical approaches, andrology, ART and an-
tioxidants. 2nd ed. Cham: Springer International Publishing; 
2020;361-75.
38. Agarwal A, Majzoub A, Baskaran S, Panner Selvam MK, Cho 
CL, Henkel R, et al. Sperm DNA fragmentation: a new guide-
line for clinicians. World J Mens Health 2020;38:412-71.
39. Dorostghoal M, Kazeminejad SR, Shahbazian N, Pourme-
hdi M, Jabbari A. Oxidative stress status and sperm DNA 
fragmentation in fertile and infertile men. Andrologia 
2017;49:e12762.
40. Ni K, Steger K, Yang H, Wang H, Hu K, Zhang T, et al. A 
comprehensive investigation of sperm DNA damage and 
oxidative stress injury in infertile patients with subclinical, 
normozoospermic, and astheno/oligozoospermic clinical 
varicocoele. Andrology 2016;4:816-24.
41. Vaughan DA, Tirado E, Garcia D, Datta V, Sakkas D. DNA 
fragmentation of sperm: a radical examination of the contri-
bution of oxidative stress and age in 16 945 semen samples. 
Hum Reprod 2020;35:2188-96.
42. Homa ST, Vassiliou AM, Stone J, Killeen AP, Dawkins A, 
Xie J, et al. A comparison between two assays for measuring 
seminal oxidative stress and their relationship with sperm 
DNA fragmentation and semen parameters. Genes (Basel) 
2019;10:236.
43. Dutta S, Henkel R, Agarwal A. Comparative analysis of tests 
used to assess sperm chromatin integrity and DNA fragmen-
tation. Andrologia 2021;53:e13718.
44. Practice Committee of the American Society for Reproduc-
tive Medicine. The clinical utility of sperm DNA integrity 
testing: a guideline. Fertil Steril 2013;99:673-7.
45. Agarwal A, Sharma R, Roychoudhury S, Du Plessis S, Sa-
banegh E. MiOXSYS: a novel method of measuring oxidation 
reduction potential in semen and seminal plasma. Fertil Steril 
2016;106:566-73.e10.
46. Elbardisi H, Finelli R, Agarwal A, Majzoub A, Henkel R, 
https://doi.org/10.5534/wjmh.210025
488 www.wjmh.org
Arafa M. Predictive value of oxidative stress testing in semen 
for sperm DNA fragmentation assessed by sperm chromatin 
dispersion test. Andrology 2020;8:610-7.
47. Agarwal A, Tvrda E, Sharma R. Relationship amongst tera-
tozoospermia, seminal oxidative stress and male infertility. 
Reprod Biol Endocrinol 2014;12:45.
48. Mayorga-Torres BJM, Camargo M, Cadavid ÁP, du Ples-
sis SS, Cardona Maya WD. Are oxidative stress markers 
associated with unexplained male infertility? Andrologia 
2017;49:e12659.
49. Wagner H, Cheng JW, Ko EY. Role of reactive oxygen species 
in male infertility: an updated review of literature. Arab J Urol 
2017;16:35-43.
50. Hamada A, Esteves SC, Nizza M, Agarwal A. Unexplained 
male infertility: diagnosis and management. Int Braz J Urol 
2012;38:576-94.
51. Venkatesh S, Shamsi MB, Deka D, Saxena V, Kumar R, Dada 
R. Clinical implications of oxidative stress & sperm DNA 
damage in normozoospermic infertile men. Indian J Med Res 
2011;134:396-8.
52. Leisegang K, Dutta S. Lifestyle management approaches to 
male infertility. In: Rizk B, Agarwal A, Sabanegh ES Jr, edi-
tors. Male infertility in reproductive medicine: diagnosis and 
management. Boca Raton (FL): CRC Press; 2019;141-51.
53. Sabeti P, Pourmasumi S, Rahiminia T, Akyash F, Talebi AR. 
Etiologies of sperm oxidative stress. Int J Reprod Biomed 
2016;14:231-40.
54. Takeshima T, Kuroda S, Yumura Y. Cancer chemotherapy and 
chemiluminescence detection of reactive oxygen species in 
human semen. Antioxidants (Basel) 2019;8:449.
55. Masic I, Miokovic M, Muhamedagic B. Evidence based 
medicine - new approaches and challenges. Acta Inform Med 
2008;16:219-25.
56. Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, 
Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. 
Cochrane Database Syst Rev 2014;(12):CD007411.
57. Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. 
Antioxidants for male subfertility. Cochrane Database Syst 
Rev 2011;(1):CD007411.
58. Agarwal A, Panner Selvam MK, Samanta L, Vij SC, Parekh N, 
Sabanegh E, et al. Effect of antioxidant supplementation on 
the sperm proteome of idiopathic infertile men. Antioxidants 
(Basel) 2019;8:488.
59. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Ka-
dioglu A, et al. EAU guidelines on sexual and reproductive 
health [Internet]. Arnhem: European Association of Urology; 
c2020 [cited 2021 Feb 20]. Available from: https://uroweb.org/
guideline/sexual-and-reproductive-health/.
60. Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg 
ML, Lamb DJ, et al. Diagnosis and treatment of infertility in 
men: AUA/ASRM guideline part I. J Urol 2021;205:36-43.
61. Turk T, Elhady MT, Rashed S, Abdelkhalek M, Nasef SA, 
Khallaf AM, et al. Quality of reporting web-based and non-
web-based survey studies: what authors, reviewers and con-
sumers should consider. PLoS One 2018;13:e0194239.
62. Silva Junior SH, Santos SM, Coeli CM, Carvalho MS. As-
sessment of participation bias in cohort studies: systematic 
review and meta-regression analysis. Cad Saude Publica 
2015;31:2259-74.
63. Bartlett JE 2nd, Kotrlik JW, Higgins CC. Organizational 
research: determining appropriate sample size in survey re-
search. Inf Technol Learn Perform J 2001;19:43–50.
64. McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, 
et al. Design and use of questionnaires: a review of best prac-
tice applicable to surveys of health service staff and patients. 
Health Technol Assess 2001;5:1-256.
65. Bergen N, Labonté R. “Everything is perfect, and we have no 
problems”: detecting and limiting social desirability bias in 
qualitative research. Qual Health Res 2020;30:783-92.
View publication stats
